Cited 0 time in
A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Bong-Ki | - |
| dc.contributor.author | Kim, Byeong-Keuk | - |
| dc.contributor.author | Park, Jae Hyoung | - |
| dc.contributor.author | Chung, Jong-Won | - |
| dc.contributor.author | Park, Chang Gyu | - |
| dc.contributor.author | Kim, Jin Won | - |
| dc.contributor.author | Kim, Young Dae | - |
| dc.contributor.author | Park, Woo-Jung | - |
| dc.contributor.author | Kim, Sang-Hyun | - |
| dc.contributor.author | Cha, Jae-Kwan | - |
| dc.contributor.author | Kim, Cheol Ho | - |
| dc.contributor.author | Rha, Seung-Woon | - |
| dc.contributor.author | Hong, Young Joon | - |
| dc.contributor.author | Shin, Mi-Seung | - |
| dc.contributor.author | Cho, Seong Wook | - |
| dc.contributor.author | Sung, Young-Hee | - |
| dc.contributor.author | Lee, Kiheon | - |
| dc.contributor.author | Yu, Jae-Myung | - |
| dc.contributor.author | Ryu, Dong-Ryeol | - |
| dc.contributor.author | Yu, Sungwook | - |
| dc.contributor.author | Song, Tae-Jin | - |
| dc.contributor.author | Ku, Bon D | - |
| dc.contributor.author | Kim, Sin-Gon | - |
| dc.contributor.author | Park, Hwan-Cheol | - |
| dc.contributor.author | Cho, Deok-Kyu | - |
| dc.contributor.author | Kim, Byung-Su | - |
| dc.contributor.author | Han, Seong-Woo | - |
| dc.contributor.author | Park, Sung-Ji | - |
| dc.contributor.author | Park, Gyung-Min | - |
| dc.contributor.author | Han, Kyoo-Rok | - |
| dc.date.accessioned | 2025-02-26T07:00:10Z | - |
| dc.date.available | 2025-02-26T07:00:10Z | - |
| dc.date.issued | 2025-01 | - |
| dc.identifier.issn | 2077-0383 | - |
| dc.identifier.issn | 2077-0383 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/206580 | - |
| dc.description.abstract | Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24–48. Secondary endpoints were assessed at weeks 24–48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52–69.32], 80.19% [95% CI 78.85–81.49], and 58.07% [95% CI 56.43–59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice. | - |
| dc.format.extent | 15 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI AG | - |
| dc.title | A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/jcm14020308 | - |
| dc.identifier.scopusid | 2-s2.0-85216097096 | - |
| dc.identifier.wosid | 001404209100001 | - |
| dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.14, no.2, pp 1 - 15 | - |
| dc.citation.title | Journal of Clinical Medicine | - |
| dc.citation.volume | 14 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 15 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | FIXED-DOSE COMBINATION | - |
| dc.subject.keywordPlus | TASK-FORCE | - |
| dc.subject.keywordPlus | PREVENTION | - |
| dc.subject.keywordPlus | CHOLESTEROL | - |
| dc.subject.keywordPlus | OLMESARTAN | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordPlus | ADHERENCE | - |
| dc.subject.keywordAuthor | blood pressure | - |
| dc.subject.keywordAuthor | dyslipidemia | - |
| dc.subject.keywordAuthor | hypertension | - |
| dc.subject.keywordAuthor | low-density lipoprotein cholesterol | - |
| dc.subject.keywordAuthor | observational study | - |
| dc.subject.keywordAuthor | single-pill combination | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
